6Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 vl. 2, Cancer Incidence and Mortality Worldwide: IARC CaneerBase No. 10 [Interact]. Lyon, France : International Agency for Research on Cancer; 2010.,Available from: http://globocan. iarc. fr, 2011- 03-12.
7Piccart M J, Bertelsen K, Stuart G, et al. Long-term fallow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over thecy combination in advancedovarian cancer[J]. Int J Gynecol Cancer,2003,13 (suppl 2) :144- 148.
8Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previouslytreated with cisplatin[J]. J Clin Oncol,1991, 9: 389-393.
9ParmarMK LJ, Colombo N, du Bois A, et al. Paclitaxel plus platinum-basedchemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: theICON4/ AGO-OVAR-2. 2 trial[J]. Lancet, 2003,361:2099-2106.
10Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of theAGO-OVAR, the NCIC CTG, and the EORTC GCG[J]. J Clin Oncol,2006, 24:4699-4707.
